glomerulonephritis

Search with Google Search with Bing
Information
Disease name
glomerulonephritis
Disease ID
DOID:2921
Description
"A nephritis that causes inflammation of the glomeruli located_in kidney." [url:http\://en.wikipedia.org/wiki/Glomerulonephritis] {comment="sn:IEDB"}
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT05174221 Active, not recruiting Phase 1 A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy November 9, 2022 March 23, 2026
NCT04663204 Active, not recruiting Phase 2 A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy December 10, 2020 March 31, 2025
NCT00004990 Completed Phase 2 Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis March 2000 December 2004
NCT00106561 Completed Phase 2/Phase 3 Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney January 2002 September 2004
NCT00345137 Completed Phase 1 Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis
NCT00426348 Completed Phase 4 A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy May 2007 January 2013
NCT00437463 Completed Phase 3 Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor July 2004 September 2010
NCT00983034 Completed N/A The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy March 2006 July 2009
NCT01093157 Completed Phase 1/Phase 2 A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy February 2010 February 2013
NCT00001457 Completed Phase 2 Lamivudine for Chronic Hepatitis B September 1995 September 2005
NCT00001676 Completed Phase 1 Cyclophosphamide and Fludarabine to Treat Lupus Nephritis January 1998 November 2002
NCT02700516 Completed Recurrent Glomerulonephritis After Renal Transplantation March 2015 April 2016
NCT03126201 Completed Predictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis December 2016 November 2017
NCT03832114 Completed Phase 2 Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted February 20, 2019 April 23, 2021
NCT03836144 Completed Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria April 2, 2015 December 31, 2020
NCT04733040 Completed Phase 2 Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE) January 20, 2021 December 14, 2023
NCT05283057 Completed Phase 3 Empagliflozin in Patients With Glomerulonephritis February 20, 2020 September 30, 2021
NCT05517980 Not yet recruiting Phase 2 Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis August 2023 September 2025
NCT05761938 Recruiting A Study of Rituximab in Frontline Therapy for Glomerulonephritis February 1, 2023 December 1, 2025
NCT05505955 Recruiting Phase 1 Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency October 8, 2022 April 10, 2023
NCT05434325 Recruiting TESTING -ON Post-Trial ObservatioNal Cohort Study December 7, 2022 July 30, 2027
NCT04662723 Recruiting Phase 4 Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. May 1, 2023 December 31, 2026
NCT04950114 Terminated Phase 2 An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases July 27, 2021 November 2, 2022
NCT04387448 Terminated Phase 2 A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease July 28, 2020 November 1, 2022
NCT00354198 Terminated Phase 3 Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis August 2006 June 2010
NCT02523768 Terminated Phase 4 Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment January 8, 2011 February 24, 2020
NCT04582890 Unknown status US Time-Harmonic Elastography for the Early Detection of Childhood Glomerulonephritis April 30, 2021 October 30, 2022
NCT02063100 Unknown status Phase 4 Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis February 2014
NCT04349683 Unknown status Phase 4 Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis April 30, 2020 October 30, 2021
NCT00862693 Unknown status Phase 4 Calcitriol in the Treatment of Immunoglobulin A Nephropathy March 2009 March 2011
NCT05383547 Unknown status N/A Bortezomib for Treating Glomerular Diseases August 2, 2022 December 31, 2023
NCT04846010 Unknown status Phase 1/Phase 2 Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 March 1, 2021 October 1, 2022
NCT04058951 Unknown status N/A Plant Versus Animal Dietary Protein and the Effect on Proteinuria August 15, 2019 July 2020
Disase is a (Disease Ontology)
DOID:10952
Cross Reference ID (Disease Ontology)
GARD:6516
Cross Reference ID (Disease Ontology)
ICD10CM:N08
Cross Reference ID (Disease Ontology)
MESH:D005921
Cross Reference ID (Disease Ontology)
NCI:C26784
Cross Reference ID (Disease Ontology)
SNOMEDCT_US_2023_03_01:36171008
Cross Reference ID (Disease Ontology)
UMLS_CUI:C0017658
HPO Human Phenotype ID (Human Phenotype Ontology)
HP:0000099
MeSH unique ID (MeSH (Medical Subject Headings))
D005921